Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.30.2 (
endonuclease
)
18,621
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Metnase
(SETMAR) is a SET and transposase fusion protein that promotes in vivo end joining activity and mediates genomic integration of foreign DNA. Recent studies showed that
Metnase
retained most of the transposase activities, including 5'-terminal inverted repeat (TIR)-specific binding and assembly of a paired end complex, and cleavage of the 5'-end of the TIR element. Here we show that R432 within the helix-turn-helix motif is critical for sequence-specific recognition, as the R432A mutation abolishes its TIR-specific DNA binding activity.
Metnase
possesses a unique DNA nicking and/or
endonuclease
activity that mediates cleavage of duplex DNA in the absence of the TIR sequence. While the HTH motif is essential for the
Metnase
-TIR interaction, it is not required for its DNA cleavage activity. The DDE-like motif is crucial for its DNA cleavage action as a point mutation at this motif (D483A) abolished its DNA cleavage activity. Together, our results suggest that
Metnase
's DNA cleavage activity, unlike those of other eukaryotic transposases, is not coupled to its sequence-specific DNA binding.
...
PMID:Biochemical characterization of a SET and transposase fusion protein, Metnase: its DNA binding and DNA cleavage activity. 1787 69
Metnase
is a fusion gene comprising a SET histone methyl transferase domain and a transposase domain derived from the Mariner transposase. This fusion gene appeared first in anthropoid primates. Because of its biochemical activities, both histone (protein) methylase and
endonuclease
, we termed the protein
Metnase
(also called SETMAR).
Metnase
methylates histone H3 lysine 36 (H3K36), improves the integration of foreign DNA, and enhances DNA double-strand break (DSB) repair by the non-homologous end joining (NHEJ) pathway, potentially dependent on its interaction with DNA Ligase IV.
Metnase
interacts with PCNA and enhances replication fork restart after stalling.
Metnase
also interacts with and stimulates TopoIIalpha-dependent chromosome decatenation and regulates cellular sensitivity to topoisomerase inhibitors used as cancer chemotherapeutics.
Metnase
has DNA nicking and
endonuclease
activity that linearizes but does not degrade supercoiled plasmids.
Metnase
has many but not all of the properties of a transposase, including Terminal Inverted Repeat (TIR) sequence-specific DNA binding, DNA looping, paired end complex formation, and cleavage of the 5' end of a TIR, but it cannot efficiently complete transposition reactions. Interestingly,
Metnase
suppresses chromosomal translocations. It has been hypothesized that transposase activity would be deleterious in primates because unregulated DNA movement would predispose to malignancy.
Metnase
may have been selected for in primates because of its DNA repair and translocation suppression activities. Thus, its transposase activities may have been subverted to prevent deleterious DNA movement.
...
PMID:Metnase/SETMAR: a domesticated primate transposase that enhances DNA repair, replication, and decatenation. 2030 21
Metnase
(SETMAR) is a SET-transposase fusion protein that promotes nonhomologous end joining (NHEJ) repair in humans. Although both SET and the transposase domains were necessary for its function in DSB repair, it is not clear what specific role
Metnase
plays in the NHEJ. In this study, we show that
Metnase
possesses a unique
endonuclease
activity that preferentially acts on ssDNA and ssDNA-overhang of a partial duplex DNA. Cell extracts lacking
Metnase
poorly supported DNA end joining, and addition of wt-
Metnase
to cell extracts lacking
Metnase
markedly stimulated DNA end joining, while a mutant (D483A) lacking
endonuclease
activity did not. Given that
Metnase
overexpression enhanced DNA end processing in vitro, our finding suggests a role for
Metnase
's
endonuclease
activity in promoting the joining of noncompatible ends.
...
PMID:Biochemical characterization of metnase's endonuclease activity and its role in NHEJ repair. 2149 84
Both
Metnase
and Artemis possess
endonuclease
activities that trim 3' overhangs of duplex DNA. To assess the potential of these enzymes for facilitating resolution of damaged ends during double-strand break rejoining, substrates bearing a variety of normal and structurally modified 3' overhangs were constructed, and treated either with
Metnase
or with Artemis plus DNA-dependent protein kinase (DNA-PK). Unlike Artemis, which trims long overhangs to 4-5 bases, cleavage by
Metnase
was more evenly distributed over the length of the overhang, but with significant sequence dependence. In many substrates,
Metnase
also induced marked cleavage in the double-stranded region within a few bases of the overhang. Like Artemis,
Metnase
efficiently trimmed overhangs terminated in 3'-phosphoglycolates (PGs), and in some cases the presence of 3'-PG stimulated cleavage and altered its specificity. The nonplanar base thymine glycol in a 3' overhang severely inhibited cleavage by
Metnase
in the vicinity of the modified base, while Artemis was less affected. Nevertheless, thymine glycol moieties could be removed by
Metnase
- or Artemis-mediated cleavage at sites farther from the terminus than the lesion itself. In in vitro end-joining systems based on human cell extracts, addition of Artemis, but not
Metnase
, effected robust trimming of an unligatable 3'-PG overhang, resulting in a dramatic stimulation of ligase IV- and XLF-dependent end joining. Thus, while both
Metnase
and Artemis are biochemically capable of resolving a variety of damaged DNA ends for the repair of complex double-strand breaks, Artemis appears to act more efficiently in the context of other nonhomologous end joining proteins.
...
PMID:Trimming of damaged 3' overhangs of DNA double-strand breaks by the Metnase and Artemis endonucleases. 2360 15